0 44

Cited 0 times in

Incidence of exudative age-related macular degeneration and treatment load under the Korean national health insurance system in 2010-2015

Authors
 Tyler Hyungtaek Rim  ;  Tae Keun Yoo  ;  Seo Hee Kim  ;  Dong Wook Kim  ;  Sung Soo Kim 
Citation
 BRITISH JOURNAL OF OPHTHALMOLOGY, Vol.103(10) : 1361-1366, 2019-10 
Journal Title
BRITISH JOURNAL OF OPHTHALMOLOGY
ISSN
 0007-1161 
Issue Date
2019-10
MeSH
Adult ; Aged ; Aged, 80 and over ; Angiogenesis Inhibitors / therapeutic use* ; Exudates and Transudates ; Female ; Follow-Up Studies ; Humans ; Incidence ; Intravitreal Injections ; Male ; Middle Aged ; National Health Programs / statistics & numerical data ; Ranibizumab / therapeutic use ; Receptors, Vascular Endothelial Growth Factor / therapeutic use ; Recombinant Fusion Proteins / therapeutic use ; Republic of Korea / epidemiology ; Retrospective Studies ; Vascular Endothelial Growth Factor A / antagonists & inhibitors ; Wet Macular Degeneration / diagnosis ; Wet Macular Degeneration / drug therapy* ; Wet Macular Degeneration / epidemiology*
Keywords
age-related macular degeneration ; retina
Abstract
Background/Aim The aim of this study was to estimate the nationwide incidence of clinically diagnosed exudative age-related macular degeneration (AMD) and associated use of ranibizumab and aflibercept in South Korea. Methods In this retrospective, population-based cohort study, claims data for 2010-2015 were analysed in a randomly selected sample of 519 661 adults aged >= 40 years. The incidence per 10 000 person-years was estimated, along with the 95% CI. Incident exudative AMD was defined based on the registration code for rare intractable diseases. Use of ranibizumab and aflibercept and the incidence of exudative AMD were recorded. Results Nine hundred and twelve patients were newly diagnosed with exudative AMD in 2010-2015. The 6-year incidence in the general population aged >= 40 years was 2.9 (95% CI 2.8 to 3.0) per 10 000 person-years. The incidence was highest in individuals aged 75-79 years (12.0, 95% CI 10.3 to 13.8). The incidence was higher in men than in women in all age groups. Six hundred and twenty-five (69%) of the 912 newly diagnosed patients started ranibizumab or aflibercept as a first-line treatment. The average number of injections administered was 6.1 (SD 3.9; minimum of 1 injection and maximum government-supported limit of 14) during 2010-2015; the number increased with increasing government funding support (from 5 to 10 and from 10 to 14 in 2013 and 2014, respectively). Conclusions This study describes the incidence of exudative AMD in South Korea and its treatment under the national health insurance system in this country. Its findings could be used for reference purposes and be useful when planning treatment for exudative AMD.
Full Text
https://bjo.bmj.com/content/103/10/1361.long
DOI
10.1136/bjophthalmol-2018-312693
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Ophthalmology (안과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Seo Hee(김서희) ORCID logo https://orcid.org/0000-0003-0319-7139
Kim, Sung Soo(김성수) ORCID logo https://orcid.org/0000-0002-0574-7993
Rim, Tyler Hyungtaek(임형택)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/189117
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links